Format

Send to

Choose Destination
Thromb Res. 1986 Apr 15;42(2):235-45.

Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.

Abstract

In a randomized pilot study we compared the antiplatelet effects of aspirin and BM 13.177 in two groups of 7 patients each undergoing PTCA. As compared with the pretreatment values template bleeding time was prolonged and collagen induced aggregation was inhibited in PRP and WB in all patients. In the course of angiography and PTCA a rise in platelet factor 4 and beta thromboglobulin was observed in both groups, followed by a decrease below the baseline levels. Thromboxane B2 in plasma and serum decreased in the aspirin group but remained unchanged during BM 13.177 treatment. In PRP and WB aggregation induced by U 46 619 was inhibited after ingestion of BM 13.177 but not following ASA. After three months a control coronary angiography was done. There was no difference in regard to the degree of restenosis between both groups. Medication was well tolerated, compliance was good and no side effects were noted.

PMID:
3012819
DOI:
10.1016/0049-3848(86)90299-9
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center